Fundraising FoxPath EX, Inc.
Houston, US · Delaware corporation · 7 known investors
Find your way into Path EX, Inc.
Sign up to see every warm intro you have to Path EX, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Path EX, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
PATH EX develops CycloPE, an extracorporeal blood purification device that removes bacteria from the bloodstream to treat sepsis in critically ill patients. The technology is designed to integrate with existing ICU workflows and can be used before pathogen identification, targeting both drug-susceptible and drug-resistant bacteria.
Founders & leadership
Board
Investors · 7
How we know: the VCSheet dataset · Not right? Tell us
How we know: Innova Memphis, Inc.'s portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$8.3M disclosed across 2 rounds · 2017–2025
▶$8.2MraisedMay 2025 · 14 investors · BiotechnologyRule 506(b)
- Sindead MillerExecutive Officer, Director
- Ehsan JabbarzadehDirector
- Jeffrey BurbankDirector
- Offering amount
- $8.2M
- Amount sold
- $8.2M
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$100KraisedMay 2017 · 2 investors · Other Health CareRule 506(b)
- Sinead MillerExecutive Officer, Director
- Alex WieselerExecutive Officer, Director
- Offering amount
- $100K
- Amount sold
- $100K
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Path EX, Inc..
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase II | 2018 | $750K |
| National Science Foundation | Phase ISTTR | 2017 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Path EX, Inc. do?
- PATH EX develops CycloPE, an extracorporeal blood purification device that removes bacteria from the bloodstream to treat sepsis in critically ill patients. The technology is designed to integrate with existing ICU workflows and can be used before pathogen identification, targeting both drug-susceptible and drug-resistant bacteria.
- Who founded Path EX, Inc.?
- Path EX, Inc. was founded by Sindead Miller.
- Who are Path EX, Inc.'s investors?
- Path EX, Inc.'s investors include Fitz Gate Ventures, Houston Angel Network, Innova Memphis, Inc., Star51 Capital, Symbiotic Ventures, Texas HALO Fund, TMC Venture Fund.
- How much funding has Path EX, Inc. raised?
- Path EX, Inc. has disclosed $8.3M raised across 2 rounds.
- Where is Path EX, Inc. headquartered?
- Path EX, Inc. is headquartered in Houston, US.